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Abstract
Objectifs: Certaines infections de prothèse ostéo-articulaire (IPO) guérissent après un lavage
articulaire avec conservation de la prothèse. Pour mieux préciser les patients candidats à cette
chirurgie conservatrice,  nous souhaitions identifier  les facteurs indépendamment associés à
son succès.
Méthodes:  Etude  observationnelle  des  IPO  initialement  traitées  par  lavage  dans  notre
institution entre 2008 et 2011, avec >6 mois de suivi post-traitement.
Résultats: Soixante patients consécutifs avec IPO (hanche, n=34; genou, n=26), ont été inclus.
Les échecs (n=20, 33%),  prédéfinis  par la persistance de signes d’IPO ou la  rechute,  ont
nécessité une chirurgie complémentaire  (n=17), et/ou une antibiothérapie suppressive (n=6).
Les  facteurs  indépendamment  associés  à  l’échec  étaient une  chirurgie  antérieure  sur  la
prothèse  (odds ratio 6.3[1.8-22.3]), une IPO à  Staphylococcus aureus (OR 9.4[1.6-53.9]) et
une durée d’antibiothérapie post-lavage <3 mois (OR 20.0[2.2-200]). 
Conclusions: Une chirurgie antérieure, une IPO à S. aureus et une antibiothérapie brève sont
associées au risque d’échec après lavage.
Mots clés: Infection de prothèse ostéo-articulaire; Staphylococcus aureus; lavage
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Abstract
Objectives: Prosthetic joint infections (PJI) may be cured in selected patients with a surgical
strategy based on debridement and prosthesis retention. To better target patients most likely to
benefit from this conservative strategy, we aimed to identify factors predictive for success. 
Methods:  We performed  an  observational  study of  PJI  initially  treated  with debridement
during years 2008-2011 in our institution, and >6 months post-treatment follow-up.
Results:  Sixty  consecutive  patients  with  PJI  (hip,  n=34;  knee,  n=26),  fulfilled  inclusion
criteria.  Failures  (n=20,  33%),  predefined  as  persistence  of  PJI  signs  or  relapses, were
managed  with  additional  surgery  (n=17),  and/or  lifelong  suppressive  antimicrobial  agents
(n=6). Variables independently associated with failure were previous surgery on the prosthetic
joint  (odds  ratio  6.3[1.8-22.3]),  Staphylococcus  aureus PJI  (OR  9.4[1.6-53.9]),  and
antibacterial treatment duration post-debridement <3 months (OR 20.0[2.2-200]).
Conclusions: Previous surgery, S. aureus PJI, and short antibacterial treatment, are associated
with increased risk of failure after debridement.
Key words: Prosthetic joint infections; Staphylococcus aureus; debridement
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1. Introduction
The burden of prosthetic joint infections (PJI) is increasing in developed countries,
due  to  increasing  number  of  patients  who underwent  arthroplasty  [1].  A recent  literature
review  estimated  that  0.9%  (95%  confidence  interval,  0.4%-2.2%)  of  primary  total  hip
arthroplasty will become infected [2]. Despite growing interest in the field, treatment of PJI
remains poorly standardized. A significant proportion of patients are initially managed with
debridement and prosthesis retention, associated with prolonged antibacterial treatment. This
conservative strategy has the theoretical advantage of simplifying the surgical procedure(s),
and may allow earlier recovery of functional joint, but success rates are sub-optimal [3-6]. To
better target the patients who are most likely to benefit from this conservative strategy, we
aimed to identify factors predictive for success.  
2. Methods
The study was performed in a 1,600-bed tertiary care center, which serves as a referral
for  the  management  of  complicated  osteo-articular  infections  in  the  area  (population
catchment,  one  million  inhabitants).  PJI  are  discussed  during  weekly  multidisciplinary
meetings with a panel of specialists in orthopedic surgery, infectious diseases, microbiology,
and radiology, in line with national and international guidelines [7,8]. Antibacterial treatment
is initiated per-operatively,  after  5 samples of infected tissues have been collected,  with a
combination  of  vancomycin/gentamicin/piperacillin-tazobactam when no indication  on  the
pathogen(s)  involved  is  available,  or  vancomycin/gentamicin  for  Gram positive  cocci,  or
piperacillin-tazobactam for  Gram negative  bacilli,  or  a  regimen  based on the pathogen(s)
susceptibility  testing,  if  available  (i.e.,  when  microbiological  documentation  have  been
obtained pre-operatively through blood cultures and/or joint aspirates).
4
We performed an observational  study of all  patients  with PJI initially treated with
debridement and prosthesis retention. Cases were identified through a computerized database,
and data  were  extracted  from medical  charts  and surgery reports,  through a  standardized
questionnaire.  Data  collected  included  demographics,  comorbidities,  PJI  diagnosis  and
management, with a special focus on surgical technique, antibacterial treatment, and follow-
up.  PJI  was  defined  by  presence  of  pus  in  the  joint,  and/or  the  growth  of  a  virulent
microorganism  (e.g.  Staphylococcus  aureus,  Gram-negative  bacilli)  in  a  specimen  of
periprosthetic  tissue,  or  synovial  fluid.  For  organism considered  as  possible  contaminant
(coagulase-negative staphylococci,  Propionibacterium acnes), at least two positive cultures
were required [7,8]. Outcome was classified as failure in case of: i) persistence of PJI signs
during treatment, or relapses after treatment discontinuation, with > 1 pathogen isolated from
osteo-articular samples, and/or ii) additional surgery required for sepsis control. Request for
informed  consent  was  waived  by  our  institutional  review  board,  as  the  study  was
retrospective, observational, and collected data anonymously. 
Quantitative  variables  were  presented  as  mean  + standard  deviation.  Qualitative
variables were expressed as percentages. Cases classified as failures were compared to cases
who did not meet criteria for failure during at least 6 months after antibacterial treatment was
discontinued, using Wilcoxon tests for quantitative variables, and Chi2 tests for qualitative
variables. To identify variables independently predictive of failure, we included all variables
with  P<0.10 in the bivariate analysis, in a multivariate logistic regression analysis step-by-
step. Statistical analysis was done with SAS 9.2 (SAS Institute, Cary, NC, USA). P<0.05 was
considered statistically significant.
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3. Results
3.1 Patients characteristics
Sixty consecutive patients with PJI (34 men, 26 women), were initially managed with
prosthesis retention and debridement in our institution during years 2008-2011 (Table I). Of
note, no striking discrepancy with guidelines was identified during medical charts review: all
patients could be candidates for debridement,  according to published criteria (i.e. PJI with
well-fixed prosthesis, without sinus tract, within 30 days of prosthetic implantation, or < 3
weeks from symptoms onset [7,8]). PJI was microbiologically documented in 54 patients,
including one polymicrobial (meticillin-susceptible S. aureus and Proteus mirabilis), 44 Gram
positive,  and  nine  Gram  negative  PJI.  Most  common  pathogens  were  S.  aureus (n=24,
including  6  meticillin-resistant),  coagulase-negative  staphylococci  (n=8,  including  6
meticillin-resistant),  and  Enterobacteriaceae.  Resistance  to  rifampin  was  found  in  two
coagulase-negative staphylococci (25%), and in no S. aureus. Resistance to fluoroquinolones
was found in six S. aureus (25%), in four coagulase-negative staphylococci (50%), and in no
Enterobacteriaceae.  Rifampin  was  prescribed  in  34  patients,  and  fluoroquinolones  in  30
patients. 
3.2 Outcome
Twenty patients (33%) presented at least one criteria for failure and were managed
with additional surgical treatment (n=17), including repeated debridement (n=6), one-stage
prosthesis exchange (n=5), two-stage prosthesis exchange (n=8), and/or life-long suppressive
antibacterial  treatment  (n=6).  Of note,  patients  could combine multiple  criteria  for failure
(e.g.,  need  for  repeated  debridement,  then  prosthesis  exchange  or  lifelong  suppressive
antibacterial  treatment).  Median  delay between antibacterial  treatment  discontinuation  and
diagnosis of failure was 30 days. 
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3.3 Risk factors for treatment failure
Variables significantly associated with failure on univariate analysis (Table II) were
previous surgery on the prosthetic joint (mean number, 0.95 + 0.18 vs. 0.48 + 0.12, P=0.03),
S. aureus PJI (60% vs. 30%, P=0.025), and duration of antimicrobial treatment (mean, 57 +
32 days vs. 101 + 55,  P=0.015). On multivariate analysis,  previous surgery (odds ratio 6.3,
CI95% [1.8-22.3]),  S. aureus PJI (OR 9.4 [1.6-53.9]),  and antibacterial  treatment duration
post-debridement  <3  months  (OR  20.0[2.2-200]) were  independently  associated  with
increased risk of failure.
4. Discussion
Initial  management  of PJI with debridement  and prosthesis  retention  is  a seducing
alternative to prosthesis replacement, and has been associated with increasing rates of success,
from 21-28% before 2000 [3-4], to 75-78% in more recent series [5-6]. However, when this
conservative strategy is applied to PJI unlikely to be cured without prosthesis removal, their
appropriate surgical management is delayed, which may lead to iterative surgeries, prolonged
antibacterial treatment, and poor functional outcome [9-14].  Hence, debridement should be
limited to patients likely to benefit from this strategy: PJI with well-fixed prosthesis, without
sinus tract, within 30 days of prosthetic implantation, or < 3 weeks from symptoms onset
[7,8].
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In this observational study, although PJI were managed by a multidisciplinary team,
with a strict adherence to guidelines, one third of those initially managed with debridement
and prosthesis retention were classified as failure, with a median follow-up of 19 months after
antibacterial  treatment  discontinuation.  Two  variables  independently  predictive  of  failure
have already been identified by others: S. aureus PJI, and multiple previous surgeries, reduce
the probability  of  success  after  debridement  with  prosthesis  retention  [7,8].  We aimed  to
identify modifiable factors associated with improved outcome: first, we found a trend toward
better  prognosis  when  debridement  was  performed  through  arthrectomy  associated  with
polyethylene  replacement  (Table  2,  P=0.08),  as  recommended  [7,8,11,15].  Second,
antibacterial  regimen  duration  <3  months  post-debridement  was  independently  associated
with failure. This suggests that PJI managed with debridement and prosthesis retention should
be treated longer than PJI managed with prosthesis replacement, which makes sense, given
that the quality of source control is probably lower when prosthesis is retained. Hence, the
remaining inoculum would be higher,  and would require  longer  duration of antimicrobial
agents. 
This study has limitations: i) as it was monocentric,  its findings do not necessarily
apply to other settings; ii) due to limited sample size, we may have missed factors associated
with treatment outcome; iii) the observational design implies that confusion bias may occur,
although the prognostic factors we identified remained significant on multivariate analysis;
iv) although  the  median  duration  of  follow-up  was  19  months  after  antibacterial
discontinuation (interquartile range, 12-27), late relapses may have been missed. Obviuosly,
randomized controlled trials will collect more robust data on optimal antibacterial treatment
duration:  For  example,  the  French  DATIPO trial,  that  has  just  been  recently  completed,
should bring ‘evidence-based’ data in this area, as patients with PJI could be enrolled whether
their  surgical  treatment  consisted  of  prosthesis  replacement,  or  prosthesis  retention  with
debridement. 
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However,  all  patients  enrolled  in  the  study  presented  herein  were  managed  by  a
multidisciplinary  team,  following  international  guidelines,  and  probably  reflect  current
management of PJI in many settings. In conclusion, this study suggests that patients with PJI
initially managed with debridement and prosthesis retention are more likely to be cured with
no  need  for  additional  surgical  interventions  if  PJI  occurred  in  the  absence  of  multiple
previous surgeries, when S. aureus is not involved, and if they receive prolonged antibacterial
treatment after debridement. 
Conflict of interest No competing interest declared
Acknowledgement The study was presented in part at the 23rdEuropean Congress of Clinical
Microbiology and Infectious Diseases, April 2013, Berlin, Germany.
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Table 1. Caractéristiques des patients
Table 1. Patients characteristics
Characteristics Number (%) or median [interquartile range]
Age (years) 75 [66-82]
Prosthetic joint involved hip, 34 (57%); knee, 26 (43%)
Comorbidities
ASA score > 2
Cardiac failure
Diabetes
20 (33%)
15 (25%)
7 (12%)
Diagnosis of prosthetic joint infection
Time from last surgery to symptoms onset (months)
Time from symptoms onset to debridement (days)
Fever > 38°C
Erythema surrounding the joint area
Purulent discharge
White blood cells count before debridement (G/mm3)
C reactive protein before debridement (mg/L)
Positive blood culture(s)
2.6 [0.5-44]
6 [4-11.5]
39 (65%)
33 (55%)
24 (40%)
10 [7-14]
142 [76-250]
19 (32%)
Debridement
Duration (minutes)
Arthrectomy and polyethylene replacement not performed
80 [60-96]
21 (35%)
Microbiology 
Meticillin-susceptible Staphylococcus aureus
Meticillin-resistant S. aureus
Coagulase-negative staphylococci
Streptococcus agalactiae
Streptococcus equisimilis
Escherichia coli
Pseudomonas aeruginosa
Others a
18 (30%)
6 (10%)
8 (13%)
5 (8%)
2 (3%)
5 (8%)
3 (5%)
8 (13%)
Antibacterial treatment duration (days) 92 [76-108]
Follow-up after antibacterials discontinuation (months)b 19 [12-27]
ASA, American Society of Anesthesiology a Proteus mirabilis, Klebsiella pneumoniae, Enterococcus faecalis,
Streptococcus mitis, Streptococcus oralis, Finegoldia magna, Propionibacterium acnes, Peptostreptococcus sp.
b Range, 6-36
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Table 2. Analyse univariée et multivariée des facteurs associés à l’échec du traitement
Table 2. Bivariate and multivariate analysis of factors associated with treatment failure
Variables
No failure
(n=40)
Failure
(n=20)
Univariate
analysis
Multivariate
analysis
P
Odds
ratio
CI 95%
Age, years 73.3 + 12.3 71.7 + 12.4 0.65
Diabetes, n (%) 4 (10) 3 (15) 0.53
ASA score > 2, n (%) 12 (30) 8 (40) 0.44
Hip prosthesis, n (%) 24 (60) 10 (50) 0.46
Previous surgery, number 0.48 + 0.12 0.95 + 0.18 0.03 6.3 [1.8-22.3]
Time from last surgery to symptoms 
onset, months
4.6 + 11 4.4 + 7.3 0.9
Time from symptoms onset to 
debridement, days
12.8 + 16.8 7.5 + 6.4 0.19
CRP before surgery, mg/dL 155.7 + 129.2 214.7 + 95.4 0.13
Positive blood cultures 11 (29) 8 (47) 0.19
CRP > 220 mg/dL, n (%) 11 (28) 8 (57) 0.053
Debridement without arthrectomy or 
polyethylene replacement, n (%)
11 (27.5) 10 (50) 0.085
Debridement duration, hours 81.9 + 31.4 94 + 57.2 0.39
Staphylococcus aureus PJI, n (%) 12 (30) 12 (60) 0.025 9.4 [1.6-53.9]
Antibacterial treatment duration, days 101.3 + 55.3 57 + 32.3 0.015
Antibacterial treatment < 3 months * 14 (38) 12 (75) 0.013 20.0 [2.2-200]
* Failures  diagnosed  while  the  patient  was still  on antibacterial  treatment  were  excluded to avoid survivor
selection bias
Continuous variables are presented as mean + standard deviation
ASA, American Society of Anesthesiology; PJI, Prosthetic Joint Infection; CI 95%, Confidence Interval 95%
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